Quarterly ResultMay 5, 2026, 07:53 AM
Neuronetics Q1 Revenue $34.5M, Up 8%; Net Loss Narrows to $(10.8)M
AI Summary
Neuronetics reported Q1 2026 revenue of $34.5 million, an 8% increase year-over-year, with U.S. clinic revenue growing 15% to $21.5 million. The net loss narrowed to $(10.8) million, or $(0.16) per share, from $(12.7) million in Q1 2025. Net cash used in operations significantly decreased by $7.6 million to $9.4 million. Additionally, Optum/UHC/UBH expanded its TMS clinical policy to allow nurse practitioners to administer NeuroStar Advanced Therapy, broadening access for approximately 34.8 million covered lives. The company maintained its full-year 2026 revenue guidance.
Key Highlights
- Q1 2026 total revenue was $34.5 million, an 8% increase year-over-year.
- U.S. clinic revenue grew 15% to $21.5 million in Q1 2026.
- Net loss for Q1 2026 narrowed to $(10.8) million, or $(0.16) per share.
- Net cash used in operations was $9.4 million, a $7.6 million reduction YoY.
- Optum/UHC/UBH expanded TMS policy to include nurse practitioners, covering 34.8 million lives.
- Shipped 34 NeuroStar systems in the US, a 10% increase compared to Q1 2025.
- Gross margin for Q1 2026 was 46.9%, down from 49.2% in Q1 2025.
- Full year 2026 revenue guidance maintained at $160 million to $166 million.